pirtobrutinib as a bridge to car-t therapy in b-cell malignancies
Published 16 hours ago • 18 plays • Length 2:11Download video MP4
Download video MP3
Similar videos
-
3:33
an overview of the car t-cell therapy story
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
1:49
a novel subcutaneous car-t therapy for the treatment of hematological malignancies
-
2:48
outcomes of autosct, allosct & car-t cell therapy in patients with tp53-altered mcl
-
1:38
challenges of car-t therapy in the real-world setting
-
1:37
the use of bispecifics and car t-cells in south america: challenges that remain
-
11:18
car-t cells: engineered cancer killers
-
3:54
kcat19: an off-the-shelf cord blood-derived allogeneic car-t product without genome editing
-
5:52
chimeric antigen receptor (car) / car-t
-
1:59
assessing if a patient with dlbcl is responding to treatment using pet-ct and novel assays
-
0:51
developing universal car-t therapies for t-all
-
3:10
universal car-t therapy for t-all
-
1:27
car t-cells in all: an overview
-
1:26
the safety and efficacy of allosct following car-t cell therapy for large b-cell lymphoma
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
1:18
the role of social media in the development of car-t therapy
-
2:30
the future of car t-cell therapy
-
4:02
the future of car-t and cellular therapy
-
1:39
the role of myeloid cells in car-t cell therapy
-
1:52
perspectives on patient selection for car-t therapy
-
0:37
hot topics in car t-cell therapy for all
-
1:42
challenges associated with car-t cell production